Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
about
P1343
MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer.Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transportersStem cell markers: ABCG2 and MCM2 expression in retinoblastomaCancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Insights into Chemoresistance of Prostate CancerRole of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceNew trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapiesFlavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol dispositionThe FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactionsSynthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance proteinHepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1.Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerizationPlasma membrane calcium ATPase (PMCA4): a housekeeper for RT-PCR relative quantification of polytopic membrane proteins.Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapyRole of drug transporters and drug accumulation in the temporal acquisition of drug resistanceTransmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2.ATP-binding cassette transporters modulate both coelenterazine- and D-luciferin-based bioluminescence imagingThe epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.Asymmetric ATP hydrolysis cycle of the heterodimeric multidrug ABC transport complex TmrAB from Thermus thermophilus.Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cellsIcotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2.Arginine 383 is a crucial residue in ABCG2 biogenesisProlonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristicsReduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry.A combination of curcumin with either gramicidin or ouabain selectively kills cells that express the multidrug resistance-linked ABCG2 transporterSildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.The challenge of exploiting ABCG2 in the clinic.Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells.Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistanceA Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma.Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.Pharmacophore-based discovery of ligands for drug transporters.Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells.Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.ABCG2 expression, function, and promoter methylation in human multiple myelomaDiscovering natural product modulators to overcome multidrug resistance in cancer chemotherapy.
P2860
Q24531336-EE6AAB1F-670E-4663-A96A-3B260553A88BQ24617999-E899B3E0-6729-4E28-A1CC-DC4F84C05C5FQ24679483-466E592C-E502-424D-A100-A262C594AB88Q26785497-9B44DCE9-1A43-473E-8798-346A6BD4EF7BQ26795589-B057D16F-EBDF-4065-BB78-ACA34BA33FC6Q26865927-AE108010-B0E2-4311-AFCE-F6F15C946B2EQ28067499-E5A7BB81-3B37-4D1B-8B2E-912B049395FAQ28475976-749294AC-879A-4EDA-B133-285E60B887ADQ28535342-63BC1494-41CF-4647-9125-1FB4BDE17F34Q30439828-C9611228-6D66-4CD9-8F64-0174FBE5EE04Q33187492-7953ABB8-BAB4-4C30-8C01-D73FF9E94CB9Q33194953-B12F5A55-0DCD-4772-800D-41E94E88BE25Q33240063-B0F18247-072B-449F-92CC-EAFA0798AAB8Q33257738-3FEC97C7-6426-41D8-AE22-FA6C4712006CQ33357010-EB0D93C3-53C9-4E84-8AF6-A7E6FC944F69Q33382292-3600B39E-DED2-49EE-8957-585044FFA8E7Q33672739-3A2EBEB7-AE5B-44F7-9237-F5EC9D9FF9B9Q33718824-304698E7-9EAE-4654-97C0-D1722C450DC2Q33738298-6813D527-5CAE-4881-9E8E-FB1D6010F585Q33753716-5E19C371-44C6-419B-B669-B9984379C068Q33781872-A89CE024-DEE5-43C5-872E-CEABE135E9DEQ33895232-AD40A19C-F484-47AE-84F0-B6C18227F75FQ34101040-0DA9CA91-9CC1-4504-9D55-C569F1565AF0Q34180165-AA442BF4-DB5E-4E81-B571-6DAACC2C67CDQ34267466-F0663D96-8607-4210-8A58-BDE4AC1F578CQ34385596-29DEBEA3-CE7E-4FAA-9EFF-5F4D14253CDDQ34393952-5D1A7218-7883-4F8B-A60A-02445DF558D9Q34467622-8C4CCD54-4356-45CE-AF3C-C48DBB3AD959Q34803651-92DA914F-98BA-40A4-9FDB-764E75D0F573Q34871636-B85BE2E3-D2BD-4965-8703-D1B00C43DBF5Q34968909-D5995731-66ED-4278-8CC7-3C9DF8E63B98Q34996536-4DD98CBC-DB5A-4847-B22B-A2C862E64C26Q35000329-5A51D682-B61E-4006-8F81-9C71132270FBQ35220471-A9A999A9-2A0B-4EEB-B188-A88395FD79B4Q35550068-B96279D8-DB75-4458-B771-A2AAD76127EEQ35594214-27D30DB2-9CD7-494F-AE78-D10032C94272Q35688446-D8F77EF0-393D-4447-8141-0CAB22AFC41AQ35837565-C1EF5974-2062-4112-A78C-A5E50EB0925BQ35848835-787E1861-9B29-4A30-B1CA-16F292F07A9AQ35915497-12113BEE-548A-4060-8F88-6BB68E0BB606
P2860
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Overexpression of the ATP-bind ...... ant human breast cancer cells.
@ast
Overexpression of the ATP-bind ...... ant human breast cancer cells.
@en
type
label
Overexpression of the ATP-bind ...... ant human breast cancer cells.
@ast
Overexpression of the ATP-bind ...... ant human breast cancer cells.
@en
prefLabel
Overexpression of the ATP-bind ...... ant human breast cancer cells.
@ast
Overexpression of the ATP-bind ...... ant human breast cancer cells.
@en
P2093
P1476
Overexpression of the ATP-bind ...... ant human breast cancer cells.
@en
P2093
A M Senderowicz
K Nishiyama
W Y Medina-Pérez
P304
P407
P4510
P577
2001-01-01T00:00:00Z